Yayın:
Vitamin D and melatonin protect the cell’s viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines

dc.contributor.authorÖzerkan, Dilşad
dc.contributor.authorÖzsoy, Nesrin
dc.contributor.authorYılmaz, Erkan
dc.date.accessioned2026-01-02T23:11:17Z
dc.date.issued2014-07-06
dc.description.abstractCarbon tetrachloride (CCl4) is widely used to induce liver toxicity in in vitro/in vivo models. Lipid peroxidation (LPO) begins with toxicity and affects cell viability. Recently, the beneficial effects of melatonin and Vitamin D on cell proliferation in human normal and cancer cells were found. This study was planned to evaluate antioxidant and cytoprotective activity of melatonin and Vitamin D in CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines. Based on the cytotoxicity assay, melatonin and Vitamin D were evaluated for cytotoprotective potential against CCl4 induced toxicity in HepG2 and Hep3B liver cell lines by monitoring cell viability, LPO and glutathione (GSH) level. Different dosages of CCl4 (0.1, 0.2, 0.3 and 0.4 % v/v) were applied to HepG2 and Hep3B cells in order to determine the most toxic dosage of it in a time dependent manner. The same experiments were repeated with exogenously applied melatonin (MEL) and Vitamin D to groups treated with/without CCL4. Cell viability was determined with MTT measurements at the 2nd, 24th and 48th h. GSH content and Malondialdehyde levels were measured from the cell lysates. As a result, both melatonin and Vitamin D administration during CCl4 exposure protected liver cells from CCl4 induced cell damage. Increase in LPO and decrease in GSH were found in the CCl4 groups of both cells. Contrary to these results administration of MEL and Vitamin D on cells exhibited results similar to the control groups. Therefore, melatonin and Vitamin D might be a promising therapeutic agent in several toxic hepatic diseases.
dc.description.urihttps://doi.org/10.1007/s10616-014-9738-8
dc.description.urihttps://europepmc.org/articles/pmc4628931?pdf=render
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/24997582
dc.description.urihttps://dx.doi.org/10.1007/s10616-014-9738-8
dc.identifier.doi10.1007/s10616-014-9738-8
dc.identifier.eissn1573-0778
dc.identifier.endpage1002
dc.identifier.issn0920-9069
dc.identifier.openairedoi_dedup___::5e137f927fc39b7f53d1030f738bd05f
dc.identifier.orcid0000-0002-0556-3879
dc.identifier.orcid0000-0002-0470-3745
dc.identifier.pubmed24997582
dc.identifier.scopus2-s2.0-84946478234
dc.identifier.startpage995
dc.identifier.urihttps://hdl.handle.net/20.500.12597/35845
dc.identifier.volume67
dc.identifier.wos000364225200009
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofCytotechnology
dc.rightsOPEN
dc.subject.sdg3. Good health
dc.titleVitamin D and melatonin protect the cell’s viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Dilşad, Özerkan","name":"Dilşad","surname":"Özerkan","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-0556-3879"},"provenance":null}},{"fullName":"Nesrin, Özsoy","name":"Nesrin","surname":"Özsoy","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0002-0470-3745"},"provenance":null}},{"fullName":"Erkan, Yılmaz","name":"Erkan","surname":"Yılmaz","rank":3,"pid":null}],"openAccessColor":"bronze","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"0303 health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Vitamin D and melatonin protect the cell’s viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines","subTitle":null,"descriptions":["Carbon tetrachloride (CCl4) is widely used to induce liver toxicity in in vitro/in vivo models. Lipid peroxidation (LPO) begins with toxicity and affects cell viability. Recently, the beneficial effects of melatonin and Vitamin D on cell proliferation in human normal and cancer cells were found. This study was planned to evaluate antioxidant and cytoprotective activity of melatonin and Vitamin D in CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines. Based on the cytotoxicity assay, melatonin and Vitamin D were evaluated for cytotoprotective potential against CCl4 induced toxicity in HepG2 and Hep3B liver cell lines by monitoring cell viability, LPO and glutathione (GSH) level. Different dosages of CCl4 (0.1, 0.2, 0.3 and 0.4 % v/v) were applied to HepG2 and Hep3B cells in order to determine the most toxic dosage of it in a time dependent manner. The same experiments were repeated with exogenously applied melatonin (MEL) and Vitamin D to groups treated with/without CCL4. Cell viability was determined with MTT measurements at the 2nd, 24th and 48th h. GSH content and Malondialdehyde levels were measured from the cell lysates. As a result, both melatonin and Vitamin D administration during CCl4 exposure protected liver cells from CCl4 induced cell damage. Increase in LPO and decrease in GSH were found in the CCl4 groups of both cells. Contrary to these results administration of MEL and Vitamin D on cells exhibited results similar to the control groups. Therefore, melatonin and Vitamin D might be a promising therapeutic agent in several toxic hepatic diseases."],"publicationDate":"2014-07-06","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Cytotechnology","issnPrinted":"0920-9069","issnOnline":"1573-0778","issnLinking":null,"ep":"1002","iss":null,"sp":"995","vol":"67","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::5e137f927fc39b7f53d1030f738bd05f","originalIds":["9738","10.1007/s10616-014-9738-8","50|doiboost____|5e137f927fc39b7f53d1030f738bd05f","od_______267::2f4d6e94fb36072e3009ca27b11d0fb7","24997582","PMC4628931","2088998206"],"pids":[{"scheme":"doi","value":"10.1007/s10616-014-9738-8"},{"scheme":"pmid","value":"24997582"},{"scheme":"pmc","value":"PMC4628931"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":20,"influence":3.1618947e-9,"popularity":7.3457516e-9,"impulse":5,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s10616-014-9738-8"}],"license":"Springer TDM","type":"Article","urls":["https://doi.org/10.1007/s10616-014-9738-8"],"publicationDate":"2014-07-06","refereed":"peerReviewed"},{"pids":[{"scheme":"doi","value":"10.1007/s10616-014-9738-8"}],"type":"Article","urls":["https://europepmc.org/articles/pmc4628931?pdf=render"],"refereed":"nonPeerReviewed"},{"pids":[{"scheme":"pmid","value":"24997582"},{"scheme":"pmc","value":"PMC4628931"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s10616-014-9738-8"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/24997582"],"publicationDate":"2015-11-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s10616-014-9738-8"},{"scheme":"mag_id","value":"2088998206"}],"type":"Article","urls":["https://dx.doi.org/10.1007/s10616-014-9738-8"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar